Peptilogics is a preclinical stage company developing a platform technology supporting a new class of broad-spectrum synthetic, engineered peptide antibiotics for multidrug-resistant (MDR) bacterial infections. We have demonstrated in vitro effectiveness against ~150 multidrug-resistant clinical isolates of the ESKAPE pathogens including MRSA, VRE, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, carbapenem-resistant Enterobacteriaceae (CRE), and colistin-resistant CRE. Our lead is efficacious when administered intravenously against lethal Pseudomonas aeruginosa bloodstream infection and E. coli urinary tract infection murine models. We have also demonstrated minimal systemic toxicity in both rat (with histology) and cynomolgus monkey (clinical pathologies) models.